Contracts › 75N93023C00015
75N93023C00015: Development of Anticeramide Treatment As a Novel Medical Countermeasure for Acute Effects of Radiation Exposure
Awarded to Ceramedix Holding, Llc by National Institutes of Health (NIH).
$4.2Mobligated
$4.2Mpotential value
30 June 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75N93023C00015 |
|---|---|
| Awardee | Ceramedix Holding, Llc |
| Awarding agency | National Institutes of Health (NIH) |
| Awarding office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | NY |
| Offers received | 16 |
| Period of performance | 01 July 2023 to 30 June 2027 |
| Potential end | 30 June 2027 |
| Estimated recompete solicitation | ~Q1 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record